27 results about "Anticoagulant therapy" patented technology

The invention relates to a lupus anticoagulant detection system and method based on a conventional blood coagulation reagent, and relates to the technical field of detection.The lupus anticoagulant detection method comprises the steps that a user sample is collected, the conventional blood coagulation reagent is adopted for conducting anticoagulant detection on the user sample, and a detection standardization ratio is obtained; acquiring similar detection data in historical time, and performing fuzzy error analysis on the detection standardization ratio by adopting a historical detection standardization ratio set in the historical detection data to obtain a fuzzy error coefficient; calculating to obtain a reagent error correction coefficient according to the fuzzy error coefficient and the conventional blood coagulation reagent error; and according to the fuzzy error coefficient, acquiring anticoagulation treatment characteristic information of the user, analyzing to obtain a user error correction coefficient, combining with a reagent error correction coefficient, performing error correction calculation on the detection standardization ratio, and obtaining a correction detection standardization ratio interval as a detection result. The technical problems that lupus anticoagulant detection conditions are deficient and the detection efficiency is low in the prior art are solved.

The invention belongs to the technical field of medical instruments, and provides a painless microneedle patch loaded with low-molecular-weight heparin and a preparation method of the painless microneedle patch in order to solve the problems that most existing microneedle products aim at small-molecular drugs, lack protection and slow release design for the low-molecular-weight heparin, low drug loading efficiency, poor activity retention and incapability of adapting to long-term anticoagulation treatment. The painless micro-needle patch comprises a substrate layer and a composite micro-needle, the composite microneedle is composed of a plurality of microneedles arranged in an array and fixed on one surface of the substrate layer and a low-molecular heparin delivery material loaded in the microneedles. According to the painless microneedle patch loaded with the low-molecular heparin, efficient percutaneous delivery of drugs can be achieved, local adverse reactions are reduced, the operation process is simplified, and the long-term drug use requirements under different anticoagulation scenes are met.

In various embodiments, disclosed herein are methods of assessing therapeutic efficacy of an anticoagulant. Preferably, the method comprising providing a blood sample; perfusing the blood sample over a surface coated with collagen or immobilized rTF; measuring platelet aggregation and fibrin deposition on the surface coated with collagen or immobilized rTF; and assessing therapeutic efficacy of the anticoagulant based on the volume of platelet aggregates and / or deposited fibrin.

Provided herein is technology relating to anticoagulant therapies and particularly, but not exclusively, to anticoagulant compositions for localized and targeted administration and related methods and kits for treatment of a subject with a localized and targeted anticoagulant therapy.

The application discloses a kind of dabigatran bleeding risk prediction methods based on machine learning, it is related to computer-aided drug risk management technical field, the method is by obtaining patient baseline and follow-up data, multiple imputation method is handled missing value;With HAS-BLED score as the basis, candidate variables are screened from potential risk factors using LassoCV algorithm, and anemia, insulin use and antifungal agent use are determined as new prediction variables through clinical correlation analysis to construct a set of prediction variables;Finally, a random forest or gradient boosting algorithm is used to train the model to output the bleeding risk assessment results of the individual to be tested.The application combines machine learning algorithm, improves the prediction accuracy of dabigatran bleeding risk in Chinese non-valvular atrial fibrillation patients, solves the problem of insufficient prediction accuracy of traditional HAS-BLED score, and provides a more reliable basis for clinical individualized anticoagulant therapy decision.

The invention provides methods and compositions for preventing or treating (e.g., slowing the progression of, arresting, and / or reversing) tissue calcification in a subject in need thereof and, more particularly, the invention relates to methods of using menaquinone-7 (MK-7) and / or menaquinol-7 (MKH2-7) for preventing or treating (e.g., slowing the progression of, arresting, and / or reversing) tissue calcification in a subject with diabetes, chronic kidney disease, end stage renal failure, or a subject undergoing hemodialysis and / or receiving anticoagulant therapy. The invention further provides methods and compositions for reducing one or more symptoms of chronic obstructive pulmonary disorder (COPD), including using menaquinone-7 (MK-7) and / or menaquinol-7 (MKH2-7), for preventing or treating (e.g., slowing the progression of, arresting, and / or reversing) one or more symptoms of COPD.

The present invention relates unit dose formulations of antidotes to anticoagulants targeting factor Xa. Disclosed herein are methods of stopping or preventing bleeding in a patient that is currently undergoing anticoagulant therapy with a factor Xa inhibitor.

The application discloses a polypeptide FXIa inhibitor FXIapepin with high inhibition and high specificity. Since FXIa can be used as a low hemorrhage risk anti-thrombus treatment target, the polypeptide inhibitor can be used for preparing a drug for developing a low hemorrhage risk treatment or prevention of a thrombotic disease, and has a wide application prospect.

A method and kit are provided for measuring and monitoring a combined effect of an anticoagulant drug on coagulation factors II and X in a patient taking the anticoagulant drug. The method includes adding one or more coagulation reagents with the factor VII to a test sample and determining blood clotability of the test sample by measuring an influence of factors II and X.

Methods of reducing the risk of venous thromboembolism (VTE) in a subject undergoing anticoagulant treatment by selectively depleting Factor V Leiden (FVL) in a subject that is heterozygous for FVL, or replacing FVL in the genome of a subject that is homozygous for FVL with a functional Factor V gene, and methods of identifying a subject undergoing anticoagulant treatment who is at risk of developing VTE are disclosed herein.

Hemorrhage and vascular instability can be induced by thrombolytic and anti-coagulant therapies. Presented herein, in certain aspects, are methods for the treatment and / or prevention of hemorrhage and vascular instability that comprise administering a compound disclosed herein to a subject in need thereof.

The invention provides methods and compositions for preventing or treating (e.g., slowing the progression of, arresting, and / or reversing) tissue calcification in a subject in need thereof and, more particularly, the invention relates to methods of using menaquinone-7 (MK-7) and / or menaquinol-7 (MKH2-7) for preventing or treating (e.g., slowing the progression of, arresting, and / or reversing) tissue calcification in a subject with diabetes, chronic kidney disease, end stage renal failure, or a subject undergoing hemodialysis and / or receiving anticoagulant therapy. The invention further provides methods and compositions for reducing one or more symptoms of chronic obstructive pulmonary disorder (COPD), including using menaquinone-7 (MK-7) and / or menaquinol-7 (MKH2-7), for preventing or treating (e.g., slowing the progression of, arresting, and / or reversing) one or more symptoms of COPD.

A method and kit are provided for monitoring anticoagulant therapy based on measuring the simultaneous influence of factors II and X only, in a test sample (i.e., test plasma or whole blood) of an anticoagulated patient, by creating a corrected sample that circumvents measuring also the influence of fibrinogen, factor V, and factor VII on the clotting process in the corrected sample. One or more coagulation reagents that activate factor VII or factor X, but not factor IX, are added to the corrected sample, and the blood clotting ability of the corrected plasma sample is subsequently determined by measuring blood clotting time. Alternatively, a reagent plasma with added factor VII is mixed into the reagent activator, such as thromboplastin, that is subsequently added to a sample of test plasma or whole blood to correct the test sample and measure the simultaneous influence of only factors II and X.

A thrombin-responsive coacervate composition comprising a coacervate comprising YR-based peptides having a thrombin cleavage sequence, an anticoagulant, and a polyphenol to stabilize the coacervate structure; and methods of using the thrombin-responsive coacervate to selectively release an anticoagulant only when thrombin is present.

Thrombolytic therapy and anticoagulant therapy can induce bleeding and vascular instability. In certain aspects, provided herein are methods for treating and / or preventing bleeding and vascular instability comprising administering a compound disclosed herein to a subject in need thereof.

The application discloses a model for predicting the risk of rivaroxaban anticoagulation bleeding and application thereof, and belongs to the technical field of biological detection. The model comprises a data input unit of two independent risk factors of a CYP3A4 genotype and clinical bleeding history of a subject, an assignment unit, an efficacy prediction unit and a report output unit, a C&B scoring system is formed according to the units, the total score is 3 points, if the C&B score is less than or equal to 1 point, rivaroxaban can be used as a coagulation factor X inhibitor for anticoagulant therapy, and if the C&B score is greater than or equal to 2 points, warfarin can be selected for anticoagulant therapy. The model can be used for guiding a clinician to accurately select a coagulation factor X inhibitor, the result of predicting the risk of rivaroxaban bleeding is accurate and reliable, and balance between anticoagulation benefits and bleeding risks can be achieved.

To provide an antibody for factor xa inhibitor and method for using the same.SOLUTION: One of the major limitations of anticoagulant therapy is the limitation of the ability to rapidly reverse anticoagulant activity in the case of treatment-related bleeding risk and in cases of overdosage or required emergency surgical intervention. Therefore, a specific effective antidote for all forms of anticoagulant therapy is highly desirable. The present invention relates to an antidote to an anticoagulant that targets factor Xa. The antidotes are factor Xa protein derivatives that bind to the factor Xa inhibitors thereby substantially neutralizing them but do not assemble into the prothrombinase complex. The derivatives described herein lack or have reduced intrinsic coagulant activity. Disclosed herein are methods of stopping or preventing bleeding in a patient that is currently undergoing anticoagulant therapy with a factor Xa inhibitor.SELECTED DRAWING: None

Methods of reducing the risk of venous thromboembolism (VTE) in a subject undergoing anticoagulant treatment by selectively depleting Factor V Leiden (FVL) in a subject that is heterozygous for FVL, or replacing FVL in the genome of a subject that is homozygous for FVL with a functional Factor V gene, and methods of identifying a subject undergoing anticoagulant treatment who is at risk of developing VTE are disclosed herein.

A method and kit are provided for monitoring anticoagulant therapy based on measuring the simultaneous influence of factors II and X only, in a test sample (i.e., test plasma or whole blood) of an anticoagulated patient, by creating a corrected sample that circumvents measuring also the influence of fibrinogen, factor V, and factor VII on the clotting process in the corrected sample. One or more coagulation reagents that activate factor VII or factor X, but not factor IX, are added to the corrected sample, and the blood clotting ability of the corrected plasma sample is subsequently determined by measuring blood clotting time. Alternatively, a reagent plasma with added factor VII is mixed into the reagent activator, such as thromboplastin, that is subsequently added to a sample of test plasma or whole blood to correct the test sample and measure the simultaneous influence of only factors II and X.

The invention provides methods and compositions for preventing or treating (e.g., slowing the progression of, arresting, and / or reversing) calciphylaxis in a subject in need thereof and, more particularly, the invention relates to methods of using menaquinone-7 (MK-7) and / or menaquinol-7 (MKH2-7) for preventing or treating calciphylaxis in a subject with one or more of the following: diabetes, chronic kidney disease, end stage renal failure, and COPD or a subject undergoing hemodialysis and / or receiving anticoagulant therapy and / or statin therapy.

This invention discloses an arterial puncture hemostasis composite dressing and its preparation method. The dressing is prepared through electrospinning, impregnation, foaming, and lamination to obtain an outer protective layer, an adaptive pressure layer, and a skin-adhesive hemostasis layer arranged sequentially from top to bottom. The skin-adhesive hemostasis layer has a polysaccharide-based composite fiber structure, loaded with procoagulant, adhesive, and antifibrinolytic components, forming an adhesive gel layer upon contact with blood. The adaptive pressure layer is an elastic porous material layer containing liquid-absorbing and swelling particles that expand in volume after absorbing blood or body fluids, generating dynamic pressure. The outer protective layer is a transparent, breathable, and waterproof polyurethane membrane. The skin-adhesive hemostasis layer maintains liquid permeability, allowing some blood to be transferred to the adaptive pressure layer to trigger expansion. This invention achieves rapid and stable hemostasis through the synergistic effects of procoagulant, adhesive, and antifibrinolytic properties, as well as the adaptive pressure mechanism, making it particularly suitable for patients undergoing anticoagulation therapy.

A method and kit are provided for measuring and monitoring a combined effect of an anticoagulant drug on coagulation factors II and X in a patient taking the anticoagulant drug. The method includes adding one or more coagulation reagents with the factor VII to a test sample and determining blood clotability of the test sample by measuring an influence of factors II and X.

The invention discloses an oral anticoagulant deoxycholic acid modified glucopyranose sulfate octasaccharide as well as a preparation method and application thereof. The octaparin-DOCA modifier is synthesized by connecting amido bonds formed by condensation of sulphated glucogalactan octasaccharide and lipophilic DOCA molecules, and the octaparin-DOCA modifier is synthesized by connecting the amido bonds with the lipophilic DOCA molecules. The octaparin-DOCA modifier disclosed by the invention shows longer anticoagulation duration and higher bioavailability after oral administration, can effectively inhibit thrombosis, has a good application prospect in the aspect of preparing an oral anticoagulant, and is particularly suitable for chronic thrombotic disease patients needing long-term anticoagulation treatment.

The invention discloses a construction method of a maternal osteoporosis model caused by exposure of low-molecular-weight heparin during pregnancy and application of the maternal osteoporosis model. A Kunming mouse is taken as an object, and 800 IU / kg of low-molecular-weight heparin is given to the mouse in the middle and late pregnancy period (9-18 days). D, after ovariectomy is conducted on 8-week-old female offspring, the 12-week-old female offspring shows the osteoporosis clinical phenotype that the number of bone trabecula, the thickness, the bone volume fraction and the bone mineral density are remarkably reduced. 15 mg / kg / d of PUPCs is synchronously supplemented in the middle and late pregnancy period, the peak bone mass of female offspring can be remarkably improved, and maternal osteoporosis is effectively prevented and treated. The model simulates the real process of female offspring maternal osteoporosis caused by clinical anticoagulation treatment, is stable in phenotype and high in repeatability, and can provide a tool for intrauterine environment interferent screening, pathogenesis exploration, early warning biomarker / intervention target discovery and prevention and treatment drug screening of maternal osteoporosis.

A single-leaflet mechanical valve, comprising a mechanical valve annulus (1), a limiting base (2), a movable valve leaflet (3), and a guide rod (4), wherein a connection hole (101) is provided in the middle of the mechanical valve annulus (1); the limiting base (2) is mounted at the bottom of the mechanical valve annulus (1), and an open movement region (201) is provided between the mechanical valve annulus (1) and the limiting base (2); and the movable valve leaflet (3) and the guide rod (4) are both located in the movement region (201), and the movable valve leaflet (3) can perform a reciprocating motion vertically along the trajectory direction of the guide rod (4), such that the movable valve leaflet (3) can movably open or close the entire channel opening of the connection hole (101), thereby relatively increasing the orifice area and achieving a lower transvalvular pressure gradient. By means of cooperation of the movable valve leaflet (3) and the guide rod (4), the mechanical valve can effectively avoid thrombosis, and is not easily damaged; and even if thrombosis occurs, the mechanical valve is not easily stuck, thus avoiding the risk of valve sticking or dysfunction, and enabling the reduction or elimination of anticoagulant therapy.

A method and kit are provided for monitoring anticoagulant therapy based on measuring the simultaneous influence of factors II and X only, in a test sample (i.e., test plasma or whole blood) of an anticoagulated patient, by creating a corrected sample that circumvents measuring also the influence of fibrinogen, factor V, and factor VII on the clotting process in the corrected sample. One or more coagulation reagents that activate factor VII or factor X, but not factor IX, are added to the corrected sample, and the blood clotting ability of the corrected plasma sample is subsequently determined by measuring blood clotting time. Alternatively, a reagent plasma with added factor VII is mixed into the reagent activator, such as thromboplastin, that is subsequently added to a sample of test plasma or whole blood to correct the test sample and measure the simultaneous influence of only factors II and X.